LIXT Lixte Biotechnology, Inc.: ערך חשבונאי למניה

The BVPS chart provided by the GURU.Markets portal demonstrates equity dynamics, while the 0.68 metric confirms the current level. Lixte Biotechnology (LIXT) seeks expansion through the development of the LB-100 platform to enhance chemotherapy. Management focuses on creating medical breakthroughs while skillfully attracting investment. Stable management adheres to R&D plans, maintaining the trust of specialized funds regarding liquidity management.

Proprietary oncology inhibitors and long-term partnerships with pharma behemoths provide a sustainable foundation for the capitalization of Lixte Biotechnology (LIXT). Book value per share data reflects the difference between total assets and liabilities, allowing investors to use this chart to assess the actual volume of the company's equity per share and track the factual dynamics of shareholder value.